MEN Syndromes

Key Mechanism 1: Loss of Tumor Suppressor Function in MEN1

• MEN1 gene encodes menin, a 610-amino acid nuclear protein that functions as a transcriptional regulator and tumor suppressor
• Menin interacts with Mixed Lineage Leukemia (MLL) histone methyltransferase complex, regulating H3K4 methylation critical for transcriptional control
• "Two-hit" Knudson hypothesis: Patients inherit one mutant allele; somatic loss of the remaining wild-type allele in endocrine tissues leads to tumor formation
• Loss of menin results in altered chromatin remodeling, aberrant gene expression, and loss of cell cycle checkpoint control
• Approximately 95% of MEN1 patients develop parathyroid tumors (multiglandular hyperplasia progressing to adenoma), 30-80% develop pancreatic neuroendocrine tumors (PNETs), and 20-65% develop anterior pituitary adenomas

Key Mechanism 2: Oncogenic RET Mutations in MEN2 Syndromes

• RET proto-oncogene (chromosome 10q11.2) encodes a receptor tyrosine kinase (RTK) critical for neural crest cell development
• In MEN2A and MEN2B, gain-of-function mutations in RET (typically in cysteine-rich extracellular domain in MEN2A; tyrosine kinase domain in MEN2B) lead to constitutive activation without ligand binding
• Activated RET autophosphorylates and phosphorylates downstream effectors (RAS/MAPK, PI3K/AKT pathways), driving uncontrolled proliferation
• In contrast to MEN1's recessive mechanism, MEN2 follows dominant inheritance with only one mutant allele required for tumorigenesis
• RET mutations virtually guarantee medullary thyroid carcinoma (MTC) development (100% penetrance by age 70 in MEN2A, earlier in MEN2B), along with pheochromocytoma (50% MEN2A, 50% MEN2B) and primary hyperparathyroidism (20-30% MEN2A, absent in MEN2B)

Key Mechanism 3: Cellular and Tissue-Specific Effects

• Parathyroid pathology in MEN1: Progressive transition from primary hyperplasia (diffuse enlargement of all four parathyroid glands with retained normal architecture) → nodular hyperplasia (multiple nodules of varying sizes) → adenomatous change (dominant nodule with suppression of surrounding tissue); histologically shows sheets of chief cells and oxyphil cells with minimal fat involution
• Pancreatic neuroendocrine tumors in MEN1: Enterochromaffin-like (ECL) cell carcinoids in stomach (due to chronic hypergastrinemia from gastrinomas); multiple gastrinomas in gastrinoma triangle (junction of cystic and common bile duct); non-functional insulinomas and other hormone-secreting tumors; histology reveals nested/trabecular growth pattern, salt-and-pepper chromatin (neuroendocrine differentiation), low mitotic rate in benign lesions
• Medullary thyroid carcinoma in MEN2: Arises from C cells (parafollicular cells) derived from neural crest; malignant potential present from earliest hyperplasia stage; histologically shows spindle cells, polygonal cells in nests, amyloid stroma (composed of misfolded calcitonin), increased mitotic activity, early lymph node metastases
• Pheochromocytoma in MEN2: Extra-adrenal tumors more common than sporadic disease; bilateral adrenal involvement in ~50% of MEN2 patients; histology shows polygonal cells with granular cytoplasm, nested architecture separated by fibrovascular septa
• Mucosal neuromas in MEN2B: Benign proliferations of nerve fibers; histology shows hyperplastic nerve bundles with increased ganglion cells in lamina propria and deeper tissues; result in distinctive lip/tongue appearance

MEN1 Syndrome

• MEN1 gene mutations (approximately 50 different identified mutations across the gene; ~10% are large deletions, ~90% are small mutations)
• Mutations scattered throughout the gene with no clear "hot spot"
• ~25% de novo mutations; remainder inherited
• Loss of the remaining wild-type allele through LOH (loss of heterozygosity) on chromosome 11q13
• Familial history (autosomal-dominant inheritance; 50% of offspring affected)
• Age-related penetrance: Nearly 100% by age 40
• No clear genotype-phenotype correlations established

MEN2A Syndrome (80% of MEN2 cases)

• RET proto-oncogene mutations in cysteine-rich extracellular domain (exons 10-11) or intracellular tyrosine kinase domain
• Codon-specific mutations associated with specific phenotypes:
• Codons 609, 611, 618, 620 (cysteine): Classic MEN2A with all three components
• Codons 768, 790, 791 (exon 13): MEN2A with prominent PHPT, variable MTC penetrance
• Codon 804 (tyrosine kinase domain): Familial medullary thyroid carcinoma (FMTC) without pheochromocytoma (distinct category)
• Familial clustering (50% offspring risk)
• Earlier MTC onset than MEN2B (age 5-25 typically)

MEN2B Syndrome (5% of MEN2 cases)

• RET proto-oncogene mutations in tyrosine kinase domain (exon 16, typically M918T)
• M918T mutation accounts for ~95% of MEN2B cases
• ~50% are de novo mutations (higher than MEN2A)
• Earlier and more aggressive MTC phenotype
• Absence of hyperparathyroidism
• Associated with distinctive mucosal neuromas, marfanoid habitus, ganglioneuromas of GI tract

Risk Factors/Modifying Factors

• Age: Tumor penetrance increases with age in MEN1; RET-mediated tumors often present in childhood/adolescence
• Genetic background: Possible modifier genes influencing phenotypic expression
• Gender: MEN1-associated hyperparathyroidism more penetrant in men; pituitary adenomas more common in women

MEN1 Syndrome Presentation

Cardinal Features (The "3 P's")

• Primary hyperparathyroidism (95% of patients by age 40)
• Chronic hypercalcemia leading to nephrolithiasis, nephrocalcinosis, osteoporosis, cognitive dysfunction
• Multiglandular hyperplasia with variable suppression of parathyroid hormone (PTH) secretion
• Mild hypercalcemia often without classic symptoms of primary hyperparathyroidism

• Pancreatic/GI neuroendocrine tumors (30-80% of patients)
• Gastrinomas (60-70% of PNETs in MEN1): Chronic diarrhea, severe GERD refractory to treatment, peptic ulcer disease; secreting excessive gastrin with low gastric pH
• Insulinomas (10-30%): Whipple triad (hypoglycemic symptoms, documented hypoglycemia <55 mg/dL, relief with glucose); often benign and solitary
• Non-functional tumors (majority): Often discovered incidentally on imaging; high malignant potential with metastases
• VIPomas, glucagonomas (rare)

• Pituitary adenomas (20-65% of patients)
• Prolactinomas (most common, 40% of pituitary adenomas): Galactorrhea, amenorrhea, decreased libido, erectile dysfunction
• Growth hormone-secreting adenomas: Acromegaly/gigantism
• Non-functional adenomas: Mass effects (bitemporal hemianopsia, headache, hypopituitarism)
• Often larger and more aggressive than sporadic adenomas

Associated Features

• Carcinoid tumors: Thymic carcinoids (5-10%, often early mortality), bronchial carcinoids (less common)
• Adrenocortical tumors (up to 40% at autopsy): Usually non-functional
• Skin manifestations: Lipomas (multiple, 30%), collagenomas (facial skin lesions), angiofibromas (formerly called adenoma sebaceum), café-au-lait spots
• Meningiomas (CNS): Often multiple, benign course

MEN2A Syndrome Presentation

Cardinal Features

• Medullary thyroid carcinoma (100% penetrance by age 70, typically age 5-50)
• C-cell hyperplasia precedes carcinoma (always present in MEN2A)
• Early lymph node metastases (by age 20 in some cases)
• Elevated calcitonin and carcinoembryonic antigen (CEA)
• Amyloid deposition histologically (misfolded calcitonin)
• Thyroid nodule, sometimes palpable; often found on screening before symptoms

• Pheochromocytoma (50% of MEN2A)
• Hypertension (often paroxysmal), palpitations, diaphoresis, headaches
• Catecholamine excess with elevated 24-hour urine metanephrines
• Bilateral in ~50% (versus 10% in sporadic disease)
• Risk of hypertensive crisis, myocardial infarction, arrhythmias

• Primary hyperparathyroidism (20-30% of MEN2A)
• Hypercalcemia, mild compared to MEN1
• Multiglandular involvement

Associated Features

• Cutaneous lichen amyloidosis (distinctive pruritic skin lesion on upper back/nape)
• Hirschsprung disease (rare)

MEN2B Syndrome Presentation

Cardinal Features (More Aggressive Phenotype)

• Medullary thyroid carcinoma (100% penetrance, earlier onset than MEN2A)
• MTC can present in childhood
• More aggressive with earlier metastases
• Highest mortality among MEN syndromes

• Pheochromocytoma (50%, similar to MEN2A)

Distinctive Features (No Hyperparathyroidism)

• Mucosal neuromas (virtually pathognomonic)
• Bumpy, enlarged lips with nodular appearance
• Neuromas on tongue, buccal mucosa, eyelid margin, GI tract
• Present from childhood

• Marfanoid habitus (tall stature, increased arm span-to-height ratio, but NOT true Marfan syndrome)
• Pectus deformities, kyphoscoliosis possible

• Intestinal ganglioneuromatosis (diffuse neural hyperplasia of GI tract)
• Chronic diarrhea, abdominal pain, constipation
• Increased risk of bowel obstruction and perforation

• Ocular manifestations: Conjunctival neuromas, corneal nerve hypertrophy

Genetic Testing

• Gold standard for confirmation: Sequencing of MEN1 gene (chromosome 11q13) or RET proto-oncogene (chromosome 10q11.2)
• Cascade genetic screening recommended for all first-degree relatives of affected individuals
• Presymptomatic testing allows early intervention in family members with mutations
• Genetic counseling essential for all patients and families

MEN1-Specific Diagnostic Criteria

• Definite MEN1: Two of the three main tumors (parathyroid, pancreatic/GI PNET, pituitary adenoma) OR one main tumor plus 2+ associated tumors (adrenocortical tumor, thymic/bronchial carcinoid, meningioma, skin lesions)
• Probable MEN1: One main tumor + one associated tumor in patient with first-degree relative with MEN1
• Familial hypocalciuric hypercalcemia (FHH) must be excluded (normal 24-hour urine calcium-to-creatinine ratio; normal PTH; differs from primary hyperparathyroidism)

Biochemical and Imaging Studies for MEN1

Parathyroid Assessment

• Serum calcium, phosphate, alkaline phosphatase, PTH, 24-hour urine calcium
• Parathyroid imaging: Sestamibi scintigraphy (most sensitive), ultrasound, CT, 4D-CT (localizes hyperfunctioning gland)
• Histopathology of resected tissue: Distinguish hyperplasia from adenoma; chief cell and oxyphil cell predominance; fat involution decreased; nodular or diffuse enlargement

Pancreatic Neuroendocrine Tumor Assessment

• Fasting serum gastrin (>1000 pg/mL highly suggestive of gastrinoma; <10 on omeprazole argues against; secretin stimulation test if borderline)
• Fasting plasma glucose, insulin, proinsulin (for insulinoma: inappropriate insulin/proinsulin suppression in setting of hypoglycemia)
• 24-hour urine 5-HIAA, plasma chromogranin A (general PNET markers)
• Endoscopic ultrasound (EUS) of pancreas (best sensitivity for small tumors <2 cm)
• MRI/CT abdomen and pelvis (tumor size, metastases)
• Somatostatin receptor imaging (octreotide scintigraphy, 68Ga-DOTATATE PET)
• Histopathology of PNET: Nested/trabecular architecture, salt-and-pepper chromatin pattern characteristic of neuroendocrine differentiation, mitotic count determines grade (Ki-67 proliferation index), amyloid deposition may be present

Pituitary Assessment

• Morning serum prolactin, free thyroxine, TSH, ACTH, cortisol (morning and midnight), IGF-1
• Pituitary MRI with contrast (detects adenomas >5 mm)
• Visual field testing if macroadenoma present
• Histopathology if surgery performed: Adenoma with specific cell type (lactotroph for prolactinoma, somatotroph for GH-secreting, gonadotroph for non-functional)

Skin Manifestation Assessment

• Clinical examination for lipomas, angiofibromas, collagenomas, café-au-lait spots

MEN2-Specific Diagnostic Approaches

Medullary Thyroid Carcinoma Screening

• Baseline and annual serum calcitonin and carcinoembryonic antigen (CEA) (calcitonin >100 pg/mL nearly diagnostic of MTC; basal calcitonin >10 warrants thyroidectomy in MEN2 mutation carriers)
• Calcitonin stimulation test (calcium gluconate or pentagastrin provocative test; increased calcitonin response indicates C-cell hyperplasia)
• Thyroid ultrasound (detects nodules >5 mm)

Stabilise first — always exclude and treat pheochromocytoma before any other operation

• Alpha blockade: nonselective irreversible alpha antagonist (phenoxybenzamine) or selective alpha-1 antagonist (doxazosin) for 1–2 weeks preoperatively, with liberal salt and fluid intake to re-expand the contracted plasma volume; the Endocrine Society pheochromocytoma guideline recommends preoperative blockade in all cases.
• Beta blockade only after alpha blockade (e.g., propranolol) for reflex tachycardia. Beta blockade first causes unopposed alpha-mediated vasoconstriction and hypertensive crisis — an absolute sequencing error on exams.
• Hypercalcemic crisis: isotonic saline first, then calcitonin for rapid effect and IV bisphosphonate (zoledronic acid) for durable control.

MEN1 — organ-directed therapy (Endocrine Society MEN1 clinical practice guideline)

• Primary hyperparathyroidism: because disease is multiglandular hyperplasia, subtotal (3.5-gland) parathyroidectomy or total parathyroidectomy with forearm autotransplantation, plus transcervical thymectomy. Single-gland excision fails.
• Gastrinoma: high-dose proton pump inhibitor (omeprazole) is first-line medical control; surgical exploration is selective because tumors are multiple and duodenal.
• Prolactinoma: dopamine agonist (cabergoline) first-line — not surgery. Somatotroph adenoma: transsphenoidal resection, then somatostatin analog (octreotide/lanreotide).
• Pancreatic NETs: resection for functioning tumors and for enlarging/larger nonfunctioning lesions; advanced disease uses somatostatin analogs, everolimus, sunitinib, or peptide receptor radionuclide therapy.

MEN2 — surgery is prophylactic (American Thyroid Association MTC guideline)

• Total thyroidectomy timing is stratified by RET codon risk: M918T (MEN2B) — highest risk, thyroidectomy in the first year of life; codon 634 — early childhood; moderate-risk codons — timing guided by serial calcitonin.
• Central compartment dissection when calcitonin or nodal imaging indicates; lifelong levothyroxine replacement afterward.
• Pheochromocytoma: laparoscopic adrenalectomy, cortical-sparing when bilateral, after blockade.
• Metastatic MTC: RET-selective kinase inhibitors (selpercatinib, pralsetinib) per NCCN.

Emergencies

• Hypertensive/catecholamine crisis (pheochromocytoma): unblocked tumor manipulation or anesthetic induction triggers massive catecholamine release → headache, diaphoresis, arrhythmia, pulmonary edema, catecholamine cardiomyopathy. Treat with IV phentolamine or nicardipine; never beta blocker alone.
• Hypercalcemic crisis: PTH-driven bone resorption and renal calcium loss with volume depletion → altered mentation, short QT, oliguria.
• Perforated or bleeding peptic ulcer (gastrinoma): unrestrained parietal-cell acid output; signals include free air on upright film or hematemesis in a patient with "refractory GERD."
• Neuroglycopenic hypoglycemia (insulinoma): seizure or coma with documented low glucose and inappropriately non-suppressed insulin/C-peptide.
• Post-thyroidectomy hypocalcemia: inadvertent parathyroid devascularization → perioral paresthesias, Chvostek and Trousseau signs, prolonged QT, laryngospasm.
• Addisonian crisis after bilateral adrenalectomy: loss of cortisol and aldosterone → hypotension, hyponatremia, hyperkalemia.

Disease complications

• Metastatic medullary thyroid carcinoma: the leading cause of death in MEN2; rising calcitonin/CEA with short doubling time signals progression, and secretory diarrhea suggests bulky hepatic disease.
• Thymic and bronchial carcinoids in MEN1: aggressive, often silent until locally advanced; disproportionate mortality in male smokers.
• Nephrolithiasis, nephrocalcinosis, osteoporosis: chronic hypercalcemia and PTH-driven cortical bone loss.
• Bowel obstruction, megacolon, or perforation from MEN2B intestinal ganglioneuromatosis.
• Mass effect from pituitary macroadenoma: bitemporal hemianopsia, hypopituitarism.

Treatment complications

• Permanent hypoparathyroidism and recurrent laryngeal nerve injury after total thyroidectomy or repeat neck exploration — hoarseness signals the latter.
• Persistent or recurrent hyperparathyroidism after subtotal parathyroidectomy, since remnant tissue carries the same germline defect.
• Multikinase inhibitor toxicity (vandetanib, cabozantinib): QT prolongation with torsades risk, hypertension, fistula formation.
• Phenoxybenzamine: orthostatic hypotension and reflex tachycardia; diazoxide: fluid retention and hyperglycemia.

• The single most tested next step: in any MEN2 patient facing surgery, screen for pheochromocytoma first (plasma free metanephrines or 24-hour urinary fractionated metanephrines) and resect it before thyroidectomy or parathyroidectomy. An unrecognized pheochromocytoma under anesthesia is the classic fatal stem.
• Mechanistic contrast examiners love: MEN1 is a tumor suppressor (menin) requiring a second somatic hit, so tumors are multifocal and age-dependent; MEN2 is a gain-of-function oncogene (RET), so a single allele suffices and the target organ is predictable — which is why prophylactic total thyroidectomy exists in MEN2 but not MEN1.
• Child with "bumpy" lips, tongue nodules, marfanoid habitus, and constipation: MEN2B from M918T; order RET testing, and expect thyroidectomy in infancy per the American Thyroid Association. MEN2B has no hyperparathyroidism.
• MTC buzzwords: sheets of spindle/polygonal C cells in an amyloid stroma that shows apple-green birefringence on Congo red; the amyloid is misfolded calcitonin. Tumor markers are calcitonin and CEA — not thyroglobulin.
• Common distractor: treating MTC with radioactive iodine or TSH suppression. C cells are neural-crest derived and not iodine-avid; levothyroxine is replacement only.
• MEN1 parathyroid disease is four-gland hyperplasia, so removing one "adenoma" recurs — subtotal or total parathyroidectomy with autotransplantation plus transcervical thymectomy is the answer.
• Prolactinoma answer is medical: cabergoline, a dopamine agonist, not transsphenoidal surgery.
• Gastrinoma pitfall: hold the PPI before measuring gastrin (PPIs raise gastrin and chromogranin A); the diagnostic combination is high gastrin with low gastric pH.
• Hypercalcemia distractor: familial hypocalciuric hypercalcemia — low urinary calcium/creatinine clearance ratio, no surgery indicated.